Revenue grew 1.0% year-over-year to KRW 3.62 trillion, with operating profit up 156.1% and net profit turning positive. F&B led growth, while retail losses narrowed and biologics investments continued. Dividend per share increased and treasury stock was canceled to enhance shareholder returns.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.